Johnson & Johnson
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson Europe sales: $5,405M in Q3 2026, down 0.6% from a year earlier.
Latest, Q3 2026
5,405
Period ended Sep 30, 2026
Change on a year earlier
-0.6%
5,440 in Q3 2025
History
40 quarters
Since Q4 2016
Sources
32
Documents cited below
Where the Q3 2026 figure comes from
Source: Form 10-Q (filed 2026-10-21) ↗
Reported in Form 10-Q / 10-K Geographic Note & Form 8-K EX-99.2.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up europe sales
Cite this data
StockData. (2026). Johnson & Johnson Europe sales ($M), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/rev-geo-europe
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.